ASX - By Stock
|
MSB |
Re:
Phase III chronic lower back pain primary end point
|
|
mr_cooper
|
57 |
27K |
4 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
57
|
27K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MPC-06-ID Phase 3 results countdown
|
|
mr_cooper
|
273 |
141K |
7 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
273
|
141K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Bitter Pill
|
|
mr_cooper
|
246 |
85K |
21 |
20/12/20 |
20/12/20 |
ASX - By Stock
|
246
|
85K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
mr_cooper
|
796 |
396K |
33 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
796
|
396K
|
33
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
mr_cooper
|
635 |
278K |
6 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
278K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial
|
|
mr_cooper
|
299 |
139K |
14 |
04/09/20 |
04/09/20 |
ASX - By Stock
|
299
|
139K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
mr_cooper
|
17K |
6.8M |
7 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
FDA ODAC Meeting Material discussion analysis
|
|
mr_cooper
|
491 |
193K |
11 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
491
|
193K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
BLA 125706 Remestemcel-L FDA briefing document
|
|
mr_cooper
|
41 |
22K |
0 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
41
|
22K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
mr_cooper
|
854 |
432K |
0 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
854
|
432K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
A thank you
|
|
mr_cooper
|
52 |
25K |
6 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
52
|
25K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
REVASCOR - CHF Insurance Coverage
|
|
mr_cooper
|
79 |
30K |
1 |
10/07/20 |
10/07/20 |
ASX - By Stock
|
79
|
30K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
REVASCOR - CHF Insurance Coverage
|
|
mr_cooper
|
79 |
30K |
4 |
10/07/20 |
10/07/20 |
ASX - By Stock
|
79
|
30K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
mr_cooper
|
933 |
437K |
14 |
14/05/20 |
14/05/20 |
ASX - By Stock
|
933
|
437K
|
14
|
|
ASX - By Stock
|
MSB |
How did MSB become a global leader?
|
|
mr_cooper
|
1 |
744 |
0 |
09/05/20 |
09/05/20 |
ASX - By Stock
|
1
|
744
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Confirmation Bias
|
|
mr_cooper
|
152 |
52K |
8 |
03/05/20 |
03/05/20 |
ASX - By Stock
|
152
|
52K
|
8
|
|
ASX - By Stock
|
OCC |
Re:
Marketing Orthocell to Professional Sport
|
|
mr_cooper
|
23 |
10K |
0 |
23/01/20 |
23/01/20 |
ASX - By Stock
|
23
|
10K
|
0
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell receives A$2.9m R&D tax incentive refund
|
|
mr_cooper
|
53 |
27K |
0 |
22/01/20 |
22/01/20 |
ASX - By Stock
|
53
|
27K
|
0
|
|
ASX - By Stock
|
OCC |
Re:
OCC chart
|
|
mr_cooper
|
2.0K |
1.0M |
0 |
02/11/19 |
02/11/19 |
ASX - By Stock
|
2.0K
|
1.0M
|
0
|
|
ASX - By Stock
|
OCC |
Re:
OCC chart
|
|
mr_cooper
|
2.0K |
1.0M |
2 |
02/11/19 |
02/11/19 |
ASX - By Stock
|
2.0K
|
1.0M
|
2
|
|